NICE issues positive FAD for Stelara

The U.K.’s NICE issued a final appraisal determination (FAD) recommending the use of Stelara ustekinumab from the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) to treat adults with moderate to severely active Crohn's disease (CD) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor (TNF) alpha antagonist or have contraindications to such therapies...